A Comparative Evaluation of Dapagliflozin and Sulfonylureas in Patients With Type 2 Diabetes Mellitus
Mohmed Sohel Shaikh, Suraj Tripathi, Chandra Bhanu Tripathi, Prashant M Parmar, Nilesh Patil, Hitesha H Trivedi · 2026
Read A Comparative Evaluation of Dapagliflozin and Sulfonylureas in Patients With Type 2 Diabetes Mellitus by Mohmed Sohel Shaikh, Suraj Tripathi, Chandra Bhanu Tripathi, Prashant M Parmar, Nilesh Patil, Hitesha H Trivedi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13600097.txt.
Description
Mohmed Sohel Shaikh and five co-authors compare two add-on diabetes drugs head to head in an Indian hospital. Their 2026 study follows 170 adults whose type 2 diabetes stayed uncontrolled on metformin alone. Half added dapagliflozin, which flushes sugar through the urine, and half added glimepiride, which prods the pancreas. Both groups were tracked for twenty-four weeks.
Both drugs worked. The newer one won the headline measure, average blood sugar over months, and added weight loss and lower blood pressure, with less of the dangerous low-sugar episodes. The older drug cut fasting sugar further. Side effects split by mechanism: more urination and genital infections on one side, more lows and tremor on the other. The authors close with a practical rule: match the drug to the patient, since the better choice depends on weight, blood pressure, and how much low-sugar risk the patient can bear.
Catalog record
| CREATOR | Mohmed Sohel Shaikh, Suraj Tripathi, Chandra Bhanu Tripathi, Prashant M Parmar, Nilesh Patil, Hitesha H Trivedi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |